Company profile for Caelum Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Caelum Biosciences, Inc. (“Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelum’s lead asset, CAEL-101 (mAb 11-1F4), is a novel antibody licensed from Columbia University in January 2017 for the treatment of amyloid light chain (“AL”) amyloidosis, a rare systemic disease that can lead to vital organ failure and death. Phase 1a/1b data presented at the...
Caelum Biosciences, Inc. (“Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelum’s lead asset, CAEL-101 (mAb 11-1F4), is a novel antibody licensed from Columbia University in January 2017 for the treatment of amyloid light chain (“AL”) amyloidosis, a rare systemic disease that can lead to vital organ failure and death. Phase 1a/1b data presented at the American Society of Hematology’s 59th Annual Meeting in December 2017, the 16th International Symposium on Amyloidosis in March 2018, the American Society of Echocardiography 29th Annual Scientific Sessions-June 2018.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Rutgers Ecocomplex, 1200 Florence Road, Bordentown, NJ 08505
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2021/10/06/2309490/28889/en/Fortress-Biotech-Announces-Closing-of-Acquisition-of-Caelum-Biosciences-by-AstraZeneca.html

GLOBENEWSWIRE
06 Oct 2021

https://www.globenewswire.com/news-release/2021/09/29/2305222/28889/en/Fortress-Biotech-Announces-Receipt-of-Notice-of-Option-Exercise-from-AstraZeneca-to-Fully-Acquire-Caelum-Biosciences-a-Company-Founded-by-Fortress-Biotech.html

GLOBENEWSWIRE
29 Sep 2021

https://www.evaluate.com/vantage/articles/news/deals/non-genetic-amyloidosis-lives-again-thanks-darzalex-and-astra

Jacob Plieth EVALUATE
29 Sep 2021

https://www.reuters.com/article/astrazeneca-caelum-biosciences/astrazeneca-buys-drugmaker-caelum-in-deal-worth-up-to-500-million-idUSKBN2GP0IG?rpc=401&

REUTERS
28 Sep 2021

https://www.businesswire.com/news/home/20210611005037/en

BUSINESSWIRE
11 Jun 2021

https://www.businesswire.com/news/home/20210611005037/en

BUSINESSWIRE
11 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty